Hepatocellular carcinoma
Conditions
Interventions
Experimental group:MWA+Apatinib+Camrelizumab
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80 years old, gender is not limited 2. Patients with primary liver cancer confirmed by histopathological or cytological examination 3. BCLC stage is B-C 4. ECOG 0-1 points 5. Child-Pugh grade A or B <=7 points 6. Tolerable surgery and no history of target-free drug allergy 7. Patients are expected to survive for more than 3 months 8. Subjects voluntarily join this study and sign the informed consent form, with good compliance.
Exclusion criteria
Exclusion criteria: 1. Diffuse liver cancer; 2. Mixed liver cancer with intrahepatic cholangiocellular carcinoma 3. Suffering from grade II. or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval >=470 ms); According to NYHA standards, cardiac insufficiency grade III.~IV., or cardiac color ultrasound examination shows that the left ventricular ejection fraction (LVEF) 1.5 or prothrombin time (PT) >ULN 4 seconds or APTT >1.5 ULN), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 5. Pregnant or lactating women; Patients of childbearing potential who are unwilling or unable to take effective contraceptive measures; 6. Have a history of mental illness or psychotropic drug abuse; 7. Combined HIV-infected patients; 8. History of esophageal (fundus) variceal rupture and bleeding; 9. Other researchers think that they are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Progression-free survival;Overall survival;Immune function indicators;Safety;Consistency analysis of therapeutic efficacy; | — |
Countries
China
Contacts
Public ContactHao Zhuang/Yan Zhao
Henan Cancer Hospital
Outcome results
None listed